Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07783308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07783308 · ClinicalTrials.gov record · last posted 2026-08-24

A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144

Name: A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144 — clinical trial record (NCT07783308)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorAstraZeneca

Started2026-08-24

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This Phase I, open-label, parallel group study will investigate the single oral dose PK, safety, and tolerability of AZD4144 to male and female participants with mild, moderate, and severe hepatic impairment compared to matched controls with normal hepatic function.

Trial Details

NCT Number	NCT07783308
Lead Sponsor	AstraZeneca
Conditions	Hepatic Impairment
Enrollment	30 participants
Start Date	2026-08-24
Primary Completion	2027-05-28 (estimated)
Study Completion	2027-05-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-24